Cyclooxygenase-2 Modulation in Liver Disease

Cyclooxygenase-2 (COX-2) is an inducible enzyme central to the biosynthesis of prostanoids, notably prostaglandin E₂, and is upregulated in a range of liver pathologies. In chronic liver conditions such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and cirrhosis, COX-2 drives inflammatory cascades, fibrogenesis and hepatocyte injury. Modulation of COX-2 activity has emerged both as a mechanistic probe and as a therapeutic strategy: selective COX-2 inhibitors can attenuate de novo lipogenesis and inflammatory signalling, while approaches that restore balanced prostaglandin production may protect against excessive cytokine release and cell death. In fibrotic settings, suppression of COX-2-derived mediators can limit activation of hepatic stellate cells, whereas in acute liver regeneration judicious COX-2 expression appears to support hepatocyte proliferation. The dual roles of COX-2 in injury and repair underscore its complex biology and its value as a target in liver disease management.

Research from Nature Portfolio

In a 2023 large-animal study, induction of NAFLD by a high-cholesterol diet led to elevated COX-2 alongside dysregulated lipolytic genes and heightened liver enzymes. Oral supplementation with Lactobacillus acidophilus normalised COX-2 expression, restored antioxidant enzyme levels and corrected lipoprotein gene profiles, demonstrating a microbiome-based route to modulate COX-2 and ameliorate steatohepatitis. An earlier mechanistic investigation in a diet-induced NASH mouse model revealed that genetic ablation of microsomal prostaglandin E synthase-1 profoundly reduced prostaglandin E₂ supply, unmasking an exaggerated TNF-α response driven by persistent COX-2 induction. The resulting surge in IL-1β and hepatocyte apoptosis highlighted the interdependence of COX-2 and downstream prostanoid pathways in regulating inflammatory homeostasis and cell survival during NASH progression.

Cyclooxygenase-2 Modulation in Liver Disease publication trend

The graph below shows the total number of articles in cyclooxygenase-2 modulation in liver disease across all publications each year (not limited to Nature Index journals).

Technical terms

Cyclooxygenase-2 (COX-2): An inducible enzyme that converts arachidonic acid to prostanoids during inflammation.

Prostaglandin E₂ (PGE₂): A bioactive lipid mediator produced by COX-2 that modulates inflammation and cell survival.

Non-alcoholic fatty liver disease (NAFLD): A spectrum of liver disorders characterised by excessive fat accumulation without significant alcohol intake.

Non-alcoholic steatohepatitis (NASH): An advanced form of NAFLD marked by inflammation, hepatocyte injury and fibrosis.

References

1. Ameliorating effect of probiotic on nonalcoholic fatty liver disease and lipolytic gene expression in rabbits. Scientific Reports (2023).
2. Augmented liver inflammation in a microsomal prostaglandin E synthase 1 (mPGES-1)-deficient diet-induced mouse NASH model. Scientific Reports (2018).
3. Low-Dose Acetylsalicylic Acid and Mitochondria-Targeted Antioxidant Mitoquinone Attenuate Non-Alcoholic Steatohepatitis in Mice. Antioxidants (2023).
4. Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt‐dependent lipogenic pathway. Journal of Cellular and Molecular Medicine (2022).
5. Liposomal quercetin: A promising strategy to combat hepatic insulin resistance and inflammation in type 2 diabetes mellitus. International Journal of Pharmaceutics (2024).